Navigation Links
The Launch and Uptake of More Than 20 Novel Drugs Over The Next 10 Years Will Drive $12.5 Billion Growth in the Type 2 Diabetes Market

Commercial Potential of Market is Reflected in Burgeoning Pipeline of More than 400 Drugs in Development, According to a New Report from Decision Resources

WALTHAM, Mass., May 20 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the launch and uptake of more than 20 novel antidiabetic drugs over the next 10 years will drive the type 2 diabetes market to increase by $12.5 billion in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The new Pharmacor report entitled Type 2 Diabetes finds that both novel and existing DPP-IV inhibitors and GLP-1 analogues - such as Merck's Januvia, Bristol-Myers Squibb/AstraZeneca's Onglyza and Amylin/Eli Lilly/Alkermes' Byetta LAR - hold the greatest promise for type 2 diabetes because these drug classes improve upon key areas of safety and efficacy. DPP-IV inhibitors have a very low risk of hypoglycemia and an excellent tolerability profile, making them suitable for widespread use. GLP-1 analogues, which combine superior glucose-lowering and weight loss capabilities compared with other drug classes, are particularly useful treatments for the significant proportion of type 2 diabetics who are obese.

"The commercial potential for drugs with demonstrated disease-modifying capabilities and long-term efficacy is reflected in the burgeoning pipeline for type 2 diabetes, which currently has more than 400 drugs in active development," said Decision Resources Analyst Christine Helliwell, Ph.D. "However, with a greater regulatory burden in the United States and an increasingly crowded market, the barriers for success are higher than ever before."

The report also finds that generic competition will weaken the market share of the PPAR-gamma agonists--Takeda's Actos and GlaxoSmithKline's Avandia--reducing sales of these agents by more than 50 percent over the 2008 to 2018 study period. The PPAR-gamma agonists, along with metformin (Bristol-Myers Squibb/Merck Sorono's Glucophage/Glucophage XR, Biovail/Depomed's Glumetza, Watson's Fortamet, generics) and the sulfonylureas, both of which are already generically available, are the most commonly prescribed first-, second-, and third-line oral therapies. Generic availability of all three drug classes will provide formidable competition for new, more-expensive drugs in the market.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

    Decision Resources               Decision Resources, Inc.
    Christopher Comfort              Elizabeth Marshall
    781-296-2597                     781-296-2563

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. American College of Physicians Chooses iPublishCentral to Launch its e-Book Strategy
2. USMLE Galaxy, LLC Launches Live and Cost Effective USMLE Review Courses and Practice Sessions Right on Your Desktop through its Subsidiary
3. Haverford Wellness Center Launches Web Site Devoted to Accurate Diagnosis and Proper Treatment to Cure Lyme Disease
4. American College of Physicians Chooses iPublishCentral to Launch its e-Book Strategy
5. Gold Star Resources Corp. Launches Humanitarian Society to Aid Liberian People
6. Photos: Will Ferrell Sunscreen to Launch Just in Time for Summer
7. Booty Camp(R) Potty Training Program as Featured in People Magazine is Launched on DVD
8. IBD Patient Launches iPhone Application to Help Doctors Treat Crohns and Ulcerative Colitis
9. Photos: USANA Launches National Rev3 Geocaching Challenge
10. ACORN CRO Launches STAR (Site Tracking and Recruitment)
11. StreetWise HSA(SM) Launched Nationally: First Low-Cost, Customizable Platform for Employee HSA Education
Post Your Comments:
(Date:11/29/2015)... ... November 29, 2015 , ... Key Housing, a top-rated corporate housing service ... 2015, featured apartment community: Epic. In showcasing this featured apartment community in San Jose, ... Area rental market to efficiently find housing suitable to their needs by showcasing quality ...
(Date:11/28/2015)... PITTSBURGH, PA (PRWEB) , ... November 28, 2015 , ... ... Manalapan, N.J., has created the COUCH BUDDY. "I conceived of this design due to ... more comfort for couch users. It promotes relaxation and convenience, as well as increases ...
(Date:11/27/2015)... (PRWEB) , ... November 28, 2015 , ... There is ... we outperform our billings from last year? , This question has not been an ... are coming to the retirement age and the younger workforce don’t share the same ...
(Date:11/27/2015)... ... ... According to an article published November 15th by ABC News, ... in light of the recent terrorist attacks in Paris, other cities are taking extra ... from reaching U.S. soil. Especially around special events that may be high-profile in nature, ...
(Date:11/27/2015)... ... November 27, 2015 , ... An inventor, from Hopkinsville, ... prescription medications at home, so he invented the patent-pending ELECTRONIC M.D. , The ... medications. In doing so, it could help to prevent potential overdose situations. As ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... PHILADELPHIA , Nov. 27, 2015  Lannett ... that it has completed the acquisition of Kremers ... pharmaceuticals subsidiary of global biopharmaceuticals company UCB S.A. ... --> Lannett has acquired KU from UCB ... to certain adjustments, including a customary working capital ...
(Date:11/26/2015)... WILMINGTON, North Carolina , 26 november ... Laboratories, Inc. (AAIPharma/CML) kondigt de geplande investering ... de uitbreiding van de laboratoria en het ... . De uitbreiding zal resulteren in ... waarmee wordt voldaan aan de groeiende behoeften ...
(Date:11/26/2015)... -- 3D bioprinting market is expected to ... report by Grand View Research Inc. Rising prevalence of chronic ... transplantation is expected to boost the market growth, as 3D ... --> 3D bioprinting market is expected to ... report by Grand View Research Inc. Rising prevalence of chronic ...
Breaking Medicine Technology: